Savara resubmits FDA application for potential treatment in rare lung disease patients
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
Appointment strengthens Medanta’s pediatric super-specialty and respiratory care services in the Delhi-NCR region.
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Subscribe To Our Newsletter & Stay Updated